Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
|
|
Reuters NewMedia - November 5, 2007
Wendell Roelf
"The explosion of tuberculosis on the continent is combined with the explosion and advance of the HIV epidemic," Zackie Achmat, the head of South Africa's Treatment Action Campaign (TAC), told Reuters in an interview in Cape Town.
"We need new TB vaccines, new TB testing and we need new TB medicines," Achmat said as he and other activists prepared for a Nov. 8 march in the city that will champion a global call for a radical programme to attack TB.
Spread through close personal contact, TB has long been a problem in Africa, where hundreds of millions of people are latent carriers. But its growing relationship with HIV has made treating both diseases more difficult in vulnerable populations.
The emergence of extensively drug resistant TB (XDR-TB), a strain virtually immune to traditional and modern antibiotics, has raised alarm bells since surfacing in South Africa's KwaZulu-Natal Province and neighbouring Lesotho in 2006, where it killed up to 85 percent of those infected.
The majority of those who died also had HIV.
The strain has since spread to other parts of Africa as well as to the industrialised world.
The prospect of a more virulent TB epidemic sweeping through Africa -- where crowded shantytowns and fragile health systems help spread the infection -- is a more serious threat because the two diseases are so prevalent and interlinked in the region.
A third of the estimated 40 million HIV-positive people worldwide are believed to be co-infected with TB and HIV. In South Africa, 61 percent of the roughly 250,000 people diagnosed with TB each year have HIV.
HIV-positive people and others with weakened immune systems are particularly vulnerable to TB as well as other opportunistic infections. But XDR-TB has led to not only higher mortality rates but also much faster deaths in HIV-positive populations.
"If XDR-TB becomes widespread and endemic it's going to cost the health system a phenomenal amount, never mind the fact that it will lead to phenomenal loss of life," said Achmat, who added that richer, industrialised nations were also not doing enough to fight TB.
The march on Thursday coincides with the opening of an international lung health conference, where experts are expected to discuss the problem of mounting resistance to TB drugs.
071105
RE071105
Copyright © 2007 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .